Guobang Pharma (SH:605507) Zheng Quan Shi Bao Wang·2025-04-02 04:21Core Viewpoint - Guobang Pharmaceutical (605507) reported strong financial performance for the fiscal year 2024, with significant growth in both revenue and net profit, highlighting its robust position in the pharmaceutical and animal health raw materials market [1][2]. Financial Performance - The company achieved a revenue of 5.891 billion yuan, a year-on-year increase of 10.12%, marking a new high since its listing [1]. - The net profit attributable to shareholders reached 782 million yuan, up 27.61% year-on-year [1]. - The net cash flow from operating activities was 706 million yuan, a substantial increase of 36.7% compared to the previous year [1]. - A cash dividend of 6 yuan per 10 shares was proposed, totaling 335 million yuan, with a payout ratio of 42.86%, the highest in three years [1]. Business Segments - Revenue from pharmaceutical raw materials was 2.477 billion yuan, growing by 11.74%, with a gross margin of 28.36%, an increase of 6.68 percentage points [3]. - Revenue from animal health raw materials reached 1.831 billion yuan, up 11.81%, maintaining a high gross margin of 18.86% [3]. - Key pharmaceutical intermediates generated revenue of 1.13 billion yuan, remaining stable year-on-year, with a gross margin of 33.2% [3]. Product Development - The company has over 38 pharmaceutical raw materials and 16 animal health raw materials approved in China, with production and sales of over 70 chemical drug products [2]. - Major products include azithromycin, clarithromycin, and ciprofloxacin, with the company being one of the largest global suppliers of macrolide and quinolone raw materials [2]. - The company has seen significant sales growth in over 20 products, with 21 products generating over 50 million yuan in revenue and 13 products exceeding 100 million yuan [3]. Global Expansion and R&D - Guobang Pharmaceutical operates a global sales network covering 115 countries, with overseas revenue of 2.664 billion yuan, an increase of 8.27% [5]. - The company invested 215 million yuan in R&D, a 12.88% increase year-on-year, with a strong team of 535 R&D personnel [6]. - A strategic partnership with Zhejiang University aims to enhance collaboration in AI, synthetic biology, and active materials [6]. Sustainability and Safety - The company invested 123 million yuan in safety and environmental protection, implementing various monitoring systems and facilities to enhance its environmental performance [7]. - The company has established a comprehensive environmental management system, contributing to its competitive edge in the market [7].